Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2026-03-30 @ 6:33 PM
Study NCT ID:
NCT00735332
Status:
TERMINATED
Last Update Posted:
2010-08-05
First Post:
2008-08-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
Sponsor:
Thallion Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TLN-232-202
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Didier Reymond, MD / Executive Vice-President Clinical Development
Old Organization:
Thallion Pharmaceuticals Inc.